Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW032 vs denosumab for prevention of skeletal-related events in solid tumor bone metastases
CTR20200407Phase 3Completed
- Sponsor
- Taikang Biopharmaceutical
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab in bone metastases, Nonhematologic neoplasms, sponsored by Taikang Biopharmaceutical. Started Mar 2020; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasesNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20200407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200407.